Development an Immune-Related MicroRNA Risk Index in Hepatocellular Carcinoma

Figure 2

Predictive capability of the IRMS. (a–c) Survival outcome between the two groups in three sets. (d–f) ROC analyses for the IRMS in three sets. (g–i) The clinical outcome of LIHC cases in three sets.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)